Biotech Values

[tony111]

The drug won't be a blockbuster but should bring in 200M annually no problem if its active in tripple negative with high GPNMB expression. The only concern is targeting the GPNB expressing tumour might provide advantage for non GPNMB expressing cancer cells to thrive. Therefore, I am not sure if it will translate to positive OS.